Table 5.

Early results with selected new therapies in development for follicular lymphoma

StudiesNumber of patientsORRCRRMain adverse events
  • Bispecific antibodies

  •  Mosunetuzumab36 

  •  Glofitamab37 

 
  • 82

  • 24

 
  • 63%

  • 68%

 
  • 43%

  • 50%

 
Cytokine release syndrome and ICANS (essentially grade 1-2), cytopenias (20%-25% grade ≥3) 
  • Chimeric antigen receptor T cells

  •  Axicabtagene ciloleucel38 

 
80 95% 81% Cytokine release syndrome (7% grade ≥3), ICANS (15% grade ≥3), cytopenias 
StudiesNumber of patientsORRCRRMain adverse events
  • Bispecific antibodies

  •  Mosunetuzumab36 

  •  Glofitamab37 

 
  • 82

  • 24

 
  • 63%

  • 68%

 
  • 43%

  • 50%

 
Cytokine release syndrome and ICANS (essentially grade 1-2), cytopenias (20%-25% grade ≥3) 
  • Chimeric antigen receptor T cells

  •  Axicabtagene ciloleucel38 

 
80 95% 81% Cytokine release syndrome (7% grade ≥3), ICANS (15% grade ≥3), cytopenias 

CRR, complete response rate; ICANS, immune effector cell–associated neurotoxicity syndrome; ORR, overall response rate.

or Create an Account

Close Modal
Close Modal